{"disease":{"id":"focal-segmental-glomerulosclerosis","name":"focal segmental glomerulosclerosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT03929887","title":"KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT00001393","title":"Genetic Markers for Focal Segmental Glomerulosclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":616,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT05200871","title":"Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)","phase":"","overall_status":"COMPLETED","enrollment_count":487,"lead_sponsor_name":"Travere Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04571658","title":"NEPTUNE Match Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":375,"lead_sponsor_name":"University of Michigan","has_results":false},{"nct_id":"NCT03493685","title":"Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":371,"lead_sponsor_name":"Travere Therapeutics, Inc.","has_results":true},{"nct_id":"NCT07220083","title":"A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":286,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT00524992","title":"Evaluation of Albuminuria HIV-Infected Patients","phase":"","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT07499700","title":"A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":192,"lead_sponsor_name":"Bio-Thera Solutions","has_results":false},{"nct_id":"NCT06443034","title":"Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":124,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06315504","title":"Circulating Factors in Nephrotic Syndrome","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":104,"lead_sponsor_name":"Iain Bressendorff","has_results":false},{"nct_id":"NCT04573920","title":"Atrasentan in Patients With Proteinuric Glomerular Diseases","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":103,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03366337","title":"A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT06162546","title":"ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Christoph Aufricht","has_results":false},{"nct_id":"NCT06500702","title":"A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05942625","title":"A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"Hansoh BioMedical R&D Company","has_results":false},{"nct_id":"NCT05003986","title":"Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":67,"lead_sponsor_name":"Travere Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02921789","title":"Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT02633046","title":"Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Mallinckrodt ARD LLC","has_results":true},{"nct_id":"NCT03448692","title":"A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":47,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03536754","title":"A Study of CCX140-B in Subjects With FSGS","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05267262","title":"Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"River 3 Renal Corp.","has_results":false},{"nct_id":"NCT03298698","title":"Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT06529796","title":"Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":false},{"nct_id":"NCT02592798","title":"Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT02235857","title":"Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children","phase":"NA","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Kaneka Medical America LLC","has_results":false},{"nct_id":"NCT04065438","title":"Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System","phase":"NA","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Kaneka Medical America LLC","has_results":false},{"nct_id":"NCT03422510","title":"FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Complexa, Inc.","has_results":false},{"nct_id":"NCT06799520","title":"A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":false},{"nct_id":"NCT05588063","title":"taVNS for FRNS in Children","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Northwell Health","has_results":false},{"nct_id":"NCT06664814","title":"An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT04369183","title":"Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease","phase":"","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Istanbul University","has_results":false},{"nct_id":"NCT00255398","title":"Kidney Disease Biomarkers","phase":"","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT03763643","title":"PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"University of Minnesota","has_results":false},{"nct_id":"NCT05955872","title":"A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":false},{"nct_id":"NCT04983888","title":"Obinutuzumab in Primary FSGS","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04088799","title":"LDL-Apheresis for FSGS CardioRenal Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Children's Hospital Medical Center, Cincinnati","has_results":false},{"nct_id":"NCT05583942","title":"A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)","phase":"NA","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Northwell Health","has_results":false},{"nct_id":"NCT03649152","title":"Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Dimerix Bioscience Pty Ltd","has_results":false},{"nct_id":"NCT04009668","title":"Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"University of Michigan","has_results":true},{"nct_id":"NCT03703908","title":"A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03598036","title":"Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Aurinia Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT05441826","title":"Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Tenet Medicines","has_results":false}],"total":43},"guidelines":[],"source":"Drug Landscape verified database"}